Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Biogen paid Ionis a US $ 60 million one-time upfront payment
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
Subscribe To Our Newsletter & Stay Updated
